DBVT (DBV Technologies) Ending Cash Position: $229.20 Mil (As of Mar. 2026)


DBVT DBV Technologies SA DBVT
31 GF Score
Price $16.08
! 1 Warning Sign
View Full Analysis

What is DBV Technologies Ending Cash Position?

DBV Technologies DBVT -4.17% 31 Ending Cash Position is $229.20 Mil as of Mar. 2026. GuruFocus rates DBVT with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

DBV Technologies's Ending Cash Position for the quarter that ended in Mar. 2026 was $229.20 Mil.

DBV Technologies's quarterly Ending Cash Position increased from Sep. 2025 ($69.84 Mil) to Dec. 2025 ($194.17 Mil) and increased from Dec. 2025 ($194.17 Mil) to Mar. 2026 ($229.20 Mil).

DBV Technologies's annual Ending Cash Position declined from Dec. 2023 ($141.37 Mil) to Dec. 2024 ($32.46 Mil) but then increased from Dec. 2024 ($32.46 Mil) to Dec. 2025 ($194.17 Mil).

DBV Technologies Ending Cash Position Related Terms

DBV Technologies Ending Cash Position Historical Data

* Premium members only.

The historical data trend for DBV Technologies's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DBV Technologies Ending Cash Position Chart

DBV Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.30 209.19 141.37 32.46 194.17

DBV Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.00 103.21 69.84 194.17 229.20
DBVT
31GF Score
DBV Technologies SA DBVT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DBV Technologies Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

DBV Technologies's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=32.455+161.712
=194.17

DBV Technologies's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=194.2+35
=229.20

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $229.20 Mil mean?
DBV Technologies (DBVT) has a Ending Cash Position of $229.20 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on DBV Technologies and its competitors.
Is DBV Technologies' Ending Cash Position too high?
DBV Technologies' current Ending Cash Position is $229.20 Mil. Overall, DBV Technologies has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' Ending Cash Position compare to VRTX and REGN?
DBV Technologies' Ending Cash Position of $229.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on DBV Technologies and its competitors. DBV Technologies's current Ending Cash Position is $229.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (DBVT) has a current Ending Cash Position of $229.20 Mil. The current Ending Cash Position is $229.20 Mil. DBV Technologies' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For DBV Technologies (DBVT), the current Ending Cash Position is $229.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DBV Technologies Business Description

Address 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score

Get the complete analysis for DBVT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.08
Price